Physiomics Raises £490,000 in Revised Placing and Launches Retail Offer to Fund Growth

Physiomics ( (GB:PYC) ) just unveiled an announcement.

Physiomics has raised £490,000 through a discounted placing of 122.5 million new shares at £0.004 each and plans to launch a WRAP retail offer of up to a further £110,000 for existing shareholders on the same terms. The revised fundraising replaces an earlier cancelled placing, removes the need for a previously called general meeting and is intended to support business development, capability expansion, personalised dosing software and exploration of strategic options as the company targets another record year of income after delivering 46% revenue growth in its last financial year.

Management says long-term shareholders have backed the business at a higher price than the scrapped March offer, signalling confidence in its growth trajectory and market expectations for FY26. The fresh capital will fund expansion of consulting services, further integration of its personalised dosing tools and corporate initiatives aimed at accelerating growth in modelling and biometrics services, potentially strengthening Physiomics’ competitive position and diversifying its customer base in the pharmaceutical services market.

The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.44 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.

Spark’s Take on PYC Stock

According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.

To see Spark’s full report on PYC stock, click here.

More about Physiomics

Physiomics plc is an AIM-listed mathematical modelling, data science and biostatistics specialist focused on supporting biotech and pharma companies in developing new therapeutics and personalised medicine. Combining modelling and simulation, biostatistics, bioinformatics and its proprietary Virtual Tumour technology, the company has delivered more than 140 commercial projects for clients including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.

Average Trading Volume: 7,523,612

Technical Sentiment Signal: Sell

Current Market Cap: £1.41M

See more data about PYC stock on TipRanks’ Stock Analysis page.